Table 3.

Patient data including histological number, treatment, gender, age and PFS

Histonumber	Treatment	Gender	Age	PFS	Staining
H 2012.13197	Encorafenib	Male	52	0
H 2012.21212
H 2012.22814
H 2011.23411	Vemurafenib	Male	33	0
H 2012.565
H 2012.3743	Vemurafenib	Male	44	1
H 2012.26647
H 2012.26648
H 2012.15227	Encorafenib	Male	37	1
H 2012.22589
H 2012.28351
H 2013.11851	Vemurafenib	Male	71	2
H 2014.3532	Vemurafenib	Female	48	3
H 2014.7225
H 2014.17199
H 2012.13943	Vemurafenib	Male	71	3
H 2012.15651
H 2012.21917‐19	Vemurafenib	Male	51	4
H 2014.9111	Vemurafenib	Female	53	4
H 2012.27219
HS2013.147
H 2012.7765	Vemurafenib	Female	73	4
H 2012.19800
H 2012.27486
H 2012.15676	Vemurafenib	Female	53	5
H 2013.13544
H 2012.6191	Vemurafenib	Female	61	5
H 2012.6826
H 2012.15122	Vemurafenib	Female	50	9
H 2013.13614
HS2014.34
H 2012.17690	Vemurafenib	Male	55	11
H 2013.18481
H 2010.25483	Vemurafenib	Male	59	21
H 2012.21406
H 2014.2708
H 2009.17175	Vemurafenib	Male	44	Stable
H 2009.21860

Histonumber	Treatment	Gender	Age	PFS	ELISA
HG12.1108	Encorafenib	Male	37	1
HG14.189	Vemurafenib	Male	71	1
HG14.281
HG14.358
HG13.1620	Vemurafenib	Female	53	4
HG14.06
HG14.525
HG14.82
HG14.1020	Encorafenib	Male	34	4
HG14.620
HG14.1096	Vemurafenib	Female	53	5
HG14.1117
HG13.1399
HG13.1622	Encorafenib	Male	60	14
HG14.1131
HG14.23
HG15.06
HG14.1069	Encorafenib	Female	30	Stable
HG15.06